Put companies on watchlist
MEDICLIN AG
ISIN: DE0006595101
WKN: 659510
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

MEDICLIN AG · ISIN: DE0006595101 · EQS - Company News (56 News)
Country: Germany · Primary market: Germany · EQS NID: 2108024
28 March 2025 10:24AM

MEDICLIN ends successful 2024 financial year


EQS-News: MEDICLIN AG / Key word(s): Annual Report/Miscellaneous
MEDICLIN ends successful 2024 financial year

28.03.2025 / 10:24 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, March 28, 2025
MEDICLIN ends successful 2024 financial year
 
MEDICLIN Aktiengesellschaft (ticker: MED; WKN 659 510) today published its annual report for the year 2024. The group generated sales of EUR 748.8 mill., which corresponds to an increase of 2.6 % compared to the previous year (2023: EUR 730.1 mill.). MEDICLIN the highest sales in thus achieved the company's history to date. At EUR 53.5 mill., the group operating result was EUR 40.8 mill. higher than the previous year's result (2023: EUR 12.7 mill.), which was heavily burdened by goodwill amortisation in the acute segment.

Dr Joachim Ramming, CEO of MEDICLIN, comments: "The development of the last financial year confirms that the strategic focus on our core competence, rehabilitation, is the right decision for the future of MEDICLIN. The acquisition of the Reha-Klinik am Sendesaal at has also brought us another step closer to our goal of becoming Germany's leading rehabilitation provider."

MEDICLIN's operating performance is emphasised even more clearly by an adjusted view of consolidated group sales and the group operating result. "Changes in the scope of consolidation, such as the acquisition of the Reha-Klinik am Sendesaal and the sale of the former MEDICLIN Herzzentrum Coswig, distort sales growth and group operating result on a relative basis", comments Tino Fritz, CFO of MEDICLIN, and adds: "Adjusted for all special effects, we were able to increase consolidated group sales by over 8 % and group operating result by over 70 %."

Developments in the segments

In the post-acute segment, sales totalled EUR 485.4 mill., up EUR 34.2 mill. or 7.6 % on the previous year. Sales do not include any significant services from the protective shield, whereas the previous year's figure included EUR 7.4 mill. The operating result for the post-acute segment of EUR 52.2 mill. corresponds to a decrease of EUR 0.5 mill. or 0.8 % compared to the previous year (2023: EUR 52.7 mill.). Adjusted for all special effects, the increase in the segment operating result corresponds to EUR 10.1 mill. or 24.7 %.

Thomas Piefke, COO of MEDICLIN, comments: "We are very satisfied with the development of our core segment post-acute, but we must not rest on our laurels. The challenging environment and the shortage of skilled labour continue to pose challenges for our industry. We are therefore continuing to work on the digitalisation and ambulantisation of our services and are consistently pursuing our strategy.”

Sales in the acute segment totalled EUR 234.8 mill. (2023: EUR 254.0 mill.). The decline in sales is mainly due to the sale of the former MEDICLIN Heart Centre Coswig. When the acute segment is adjusted for all special effects, an adjusted increase of 8.7% was achieved. An operating result of EUR -0.6 mill. was achieved in the acute segment (previous year: EUR -39.9 mill.). The segment's operating result in 2023 was significantly impacted by the one-off effect of goodwill amortisation for three facilities - totalling EUR 33.1 mill. When considering the segment operating result adjusted for all special effects, this corresponds to an adjusted increase of EUR 9.1 mill.

Sales in the nursing care segment rose to EUR 23.4 mill. in the reporting year (2023: EUR 21.3 mill.), while the segment operating result reached EUR 0.2 mill., as in the previous year.

Sales in the Service segment increased by EUR 13.3 mill. to EUR 94.6 mill. At EUR 1.7 mill., the segment operating result was EUR 2.0 mill. higher than in the previous year (2023: EUR -0.3 mill.).

Further information on developments in the segments and detailed reconciliation tables for adjusted sales and operating results can be in the 2024 Annual Report under Investor Relations. MEDICLIN has decided to stop printing its annual report in order to make a contribution to environmental protection and protect resources.


Outlook 2025

The stable utilisation rate and the adjustments to MEDICLIN's portfolio make the Management Board optimistic about the business outlook for 2025. The Management Board anticipates sales growth for the group of 2.0 % to 5.0 %. Group EBIT is expected to be between EUR 53.0 mill. and EUR 64.0 mill.

For more information:

MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg
Germany

Investor Relations
Ender Gülcan
Phone +49 781/488-326
ender.guelcan@mediclin.de



www.mediclin.de

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 31 clinics, six care facilities and ten medical care centers. The group has around 8,200 beds/care places and employs around 9,900 people.
In a strong network, MEDICLIN offers the patients integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group
 


28.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MEDICLIN AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: ender.guelcan@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2108024

 
End of News EQS News Service

2108024  28.03.2025 CET/CEST

Visual performance / price development - MEDICLIN AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.